Back to today’s briefing

Story perspectives

Johnson & Johnson to Spin Off DePuy Synthes Division

10/14/2025

42 5 Full Breakdown

Summary

Story summary

Johnson & Johnson announced plans to spin off DePuy Synthes within 18 to 24 months.
This would be Johnson & Johnson's second major separation since spinning off its consumer health unit in 2023.
Last year the orthopedics division generated about $9.2 billion in sales, roughly 10% of revenue.
Johnson & Johnson raised its 2025 sales forecast to between $93.5 billion and $93.9 billion.
The stock fell about 1% in early trading.

History

Historical Context

In 2023, Johnson & Johnson spun off its consumer health unit, Kenvue, a move reflecting a trend in corporate restructuring to enhance focus and profitability. DePuy Synthes, acquired in 1998, generated $9.2 billion in sales, highlighting its significance within J&J's MedTech segment. This strategic shift aims to increase market competitiveness and streamline operations, following a history of legal challenges related to product recalls.

1 of 2

Story summary

Johnson & Johnson announced plans to spin off DePuy Synthes within 18 to 24 months.
This would be Johnson & Johnson's second major separation since spinning off its consumer health unit in 2023.
Last year the orthopedics division generated about $9.2 billion in sales, roughly 10% of revenue.
Johnson & Johnson raised its 2025 sales forecast to between $93.5 billion and $93.9 billion.
The stock fell about 1% in early trading.

1 / 2